Novel (p-Tolyl)-3(2H)-Pyridazinone Derivatives Containing Substituted-1,2,3-Triazole Moiety as New Anti-Alzheimer Agents: Synthesis, In vitro and In silico Assays; [1,2,3-Triazol Uygulaması Yeni Anti-Alzheimer (P-Tolil)-3(2H)-Piridazinon Türevleri: Sentez Çalışmaları, in vitro ve in siliko Analizleri]

ArticleAçık Erişim

Özet

Alzheimer’s disease (AD) is a chronic neurodegenerative disease that is the most common cause of dementia. The risk of developing the disease increases with age. When the histopathology of the disease is examined, senile amyloid plaques, neurofibrillary tangle formation, synapse-neuron loss, and marked atrophy in the brain are detected. The decrease in the level of choline acetyltransferase, which is responsible for the synthesis of acetylcholine in Alzheimer’s disease, is 58-90%. There is a great need for new drugs that target the basis of the cause of the disease, as existing drugs cannot stop the progression of the disease. In this study, triazole-pyridazinone derivative compounds showing acetylcholinesterase inhibition were synthesized and their inhibitions were investigated. Compound 6e exhibited the strongest inhibitory effect with a Ki value of 0.049 ± 0.014 µM (Tacrine Ki= 0.226 ± 0.025 µM). In addition, in silico studies were applied for all compounds. © 2022 Society of Pharmaceutical Sciences of Ankara (FABAD). All rights reserved.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/12555Resmi atıflarda kullanılan kalıcı adres
Tam Kayıt
AlanDeğerDil
dc.contributor.authorBozbey Merde, İrem
dc.contributor.authorTaşkor Önel, Gülce
dc.contributor.authorTürkmenoğlu, Burçin
dc.contributor.authorGürsoy, Şule
dc.contributor.authorDi̇Lek, Esra
dc.date.accessioned2026-10-18T20:27:26.778532397Z
dc.date.available2026-10-18T20:27:26.778532397Z
dc.date.issued2022
dc.description.abstractAlzheimer’s disease (AD) is a chronic neurodegenerative disease that is the most common cause of dementia. The risk of developing the disease increases with age. When the histopathology of the disease is examined, senile amyloid plaques, neurofibrillary tangle formation, synapse-neuron loss, and marked atrophy in the brain are detected. The decrease in the level of choline acetyltransferase, which is responsible for the synthesis of acetylcholine in Alzheimer’s disease, is 58-90%. There is a great need for new drugs that target the basis of the cause of the disease, as existing drugs cannot stop the progression of the disease. In this study, triazole-pyridazinone derivative compounds showing acetylcholinesterase inhibition were synthesized and their inhibitions were investigated. Compound 6e exhibited the strongest inhibitory effect with a Ki value of 0.049 ± 0.014 µM (Tacrine Ki= 0.226 ± 0.025 µM). In addition, in silico studies were applied for all compounds. © 2022 Society of Pharmaceutical Sciences of Ankara (FABAD). All rights reserved.
dc.description.sponsorshipThe authors would like to thank Erzincan Binali Yıldırım University, Basic Sciences Application and Research Center (EBYU-EUTAM) for the Schrödinger Maestro 2021-2 program.
dc.identifier.doi10.55262/fabadeczacilik.1128446
dc.identifier.eissn2651-4648
dc.identifier.endpage368
dc.identifier.issn1300-4182
dc.identifier.issue3
dc.identifier.scopus2-s2.0-85160877335
dc.identifier.startpage355
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/12555
dc.identifier.volume47
dc.language.isoen
dc.publisherSociety of Pharmaceutical Sciences of Ankara (FABAD)
dc.relation.ispartofFabad Journal of Pharmaceutical Sciences
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subject3(2H)-pyridazinone
dc.subjectacetylcholinesterase
dc.subjectmolecular docking
dc.subject(para tolyl) 3(2h) pyridazinone derivative
dc.subject2 [2 (4 phenyl 5 thioxo 4,5 dihydro 1h 1,2,4 triazol 3 yl)ethyl] 6 (para tolyl)pyridazin 3(2h) one
dc.subject2 [2 [4 (2 methoxyphenyl) 5 thioxo 4,5 dihydro 1h 1,2,4 triazol 3 yl)ethyl] 6 (para tolyl)pyridazin 3(2h) one
dc.subject2 [2 [4 (4 bromophenyl) 5 thioxo 4,5 dihydro 1h 1,2,4 triazol 3 yl)ethyl] 6 (para tolyl)pyridazin 3(2h) one
dc.subject2 [2 [5 thioxo 4 (para tolyl) 4,5 dihydro 1h 1,2,4 triazol 3 yl] ethyl] 6 (para tolyl)pyridazin 3(2h) one
dc.subject2 [2 [5 thioxo 4 [4 (trifluoromethoxy)phenyl] 4,5 dihydro 1h 1,2,4 triazol 3 yl]ethyl 6 (para tolyl)pyridazin 3 (2h) one
dc.subjectcholinesterase inhibitor
dc.subjectnootropic agent
dc.subjectpyridazinone derivative
dc.subjecttacrine
dc.subjectunclassified drug
dc.subjectAlzheimer disease
dc.subjectArticle
dc.subjectcarbon nuclear magnetic resonance
dc.subjectcholinesterase inhibition
dc.subjectcomputer model
dc.subjectcontrolled study
dc.subjectcrystal structure
dc.subjectdrug synthesis
dc.subjectenzyme inhibition
dc.subjectgene expression
dc.subjectIC50
dc.subjectin vitro study
dc.subjectprotein expression
dc.subjectproton nuclear magnetic resonance
dc.subjectroom temperature
dc.subjectstructure activity relation
dc.titleNovel (p-Tolyl)-3(2H)-Pyridazinone Derivatives Containing Substituted-1,2,3-Triazole Moiety as New Anti-Alzheimer Agents: Synthesis, In vitro and In silico Assays; [1,2,3-Triazol Uygulaması Yeni Anti-Alzheimer (P-Tolil)-3(2H)-Piridazinon Türevleri: Sentez Çalışmaları, in vitro ve in siliko Analizleri]
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus13
rdl.citation.trdizin0
rdl.departmentERZİNCAN BİNALİ YILDIRIM ÜNİVERSİTESİ
rdl.oa.statusgreen
rdl.source.indexSCOPUS
rdl.source.indexTRDIZIN